|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US11885806B2
(en)
|
2014-03-05 |
2024-01-30 |
Autolus Limited |
Method for depleting malignant T-cells
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
DK3579848T3
(da)
|
2017-02-08 |
2025-01-20 |
Dragonfly Therapeutics Inc |
Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
KR20240060739A
(ko)
|
2017-02-20 |
2024-05-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Her2, nkg2d 및 cd16에 결합하는 단백질
|
|
WO2019018828A1
(en)
*
|
2017-07-20 |
2019-01-24 |
Cytomx Therapeutics, Inc. |
METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
|
|
KR102172092B1
(ko)
|
2017-09-19 |
2020-10-30 |
주식회사 엘지화학 |
열가소성 수지 조성물, 이의 제조방법 및 성형품
|
|
SI3694529T1
(sl)
|
2017-10-13 |
2024-10-30 |
Harpoon Therapeutics, Inc. |
Trispecifične beljakovine in načini uporabe
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
AU2018351956A1
(en)
*
|
2017-10-20 |
2020-04-23 |
Nantbio, Inc. |
Methods for monitoring bladder cancer immunotherapy
|
|
SG11202007579TA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
CN111989108B
(zh)
*
|
2018-02-13 |
2024-07-16 |
嵌合体生物工程公司 |
利用rna去稳定元件协调基因表达
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
WO2019195408A1
(en)
*
|
2018-04-03 |
2019-10-10 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
|
UY38182A
(es)
*
|
2018-04-10 |
2019-10-31 |
Amgen Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
|
IL277863B2
(en)
|
2018-04-11 |
2026-02-01 |
Inhibrx Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
WO2019217145A1
(en)
|
2018-05-08 |
2019-11-14 |
Phanes Therapeutics, Inc. |
Anti-dll3 antibodies and uses thereof
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EP3833385A4
(en)
|
2018-08-08 |
2021-12-22 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
AU2019336245B2
(en)
|
2018-09-07 |
2026-02-26 |
Beam Therapeutics Inc. |
Compositions and methods for delivering a nucleobase editing system
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020114518A1
(zh)
*
|
2018-12-07 |
2020-06-11 |
科济生物医药（上海）有限公司 |
肿瘤联合免疫治疗
|
|
CN114040977B
(zh)
|
2019-01-31 |
2024-09-03 |
比姆医疗股份有限公司 |
非靶脱氨反应减低的核碱基编辑器和用于定性核碱基编辑器的测定
|
|
SG11202108346WA
(en)
|
2019-02-13 |
2021-08-30 |
Beam Therapeutics Inc |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
AU2020223314A1
(en)
|
2019-02-13 |
2021-08-12 |
Beam Therapeutics Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
US11673953B2
(en)
*
|
2019-03-01 |
2023-06-13 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
|
WO2020182517A1
(en)
*
|
2019-03-08 |
2020-09-17 |
Oncolab Diagnostics Gmbh |
Cancer diagnosis and prognosis
|
|
US20220184127A1
(en)
*
|
2019-04-08 |
2022-06-16 |
Phanes Therapeutics, Inc. |
Humanized anti-dll3 chimeric antigen receptors and uses thereof
|
|
KR20220008866A
(ko)
|
2019-05-14 |
2022-01-21 |
하푼 테라퓨틱스, 인크. |
EpCAM 결합 단백질 및 사용 방법
|
|
TW202535924A
(zh)
*
|
2019-07-17 |
2025-09-16 |
大陸商南京傳奇生物科技有限公司 |
抗ｄｌｌ３嵌合抗原受體及其用途
|
|
EP4013431A4
(en)
*
|
2019-08-18 |
2024-05-01 |
Chimera Bioengineering, Inc. |
Combination therapy with gold controlled transgenes
|
|
CN115279398B
(zh)
|
2019-09-27 |
2025-07-04 |
比姆医疗股份有限公司 |
治疗液态癌症的组合物和方法
|
|
IL294879A
(en)
|
2020-01-29 |
2022-09-01 |
Inhibrx Inc |
Monodomain antibodies of cd28 and their multivalent and multispecific constructs
|
|
KR20220162690A
(ko)
*
|
2020-01-31 |
2022-12-08 |
젠선 바이오파마, 인코포레이티드 |
이중특이성 t 세포 관여항체
|
|
US12486331B2
(en)
|
2020-01-31 |
2025-12-02 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
US12606635B2
(en)
|
2020-03-12 |
2026-04-21 |
Nanjing Legend Biotech Co., Ltd. |
Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN113444172A
(zh)
*
|
2020-03-25 |
2021-09-28 |
兴盟生物医药(苏州)有限公司 |
金黄色葡萄球菌α-毒素特异性抗体及其应用
|
|
CN115836088A
(zh)
|
2020-05-06 |
2023-03-21 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和clec12a的蛋白质
|
|
US12576151B2
(en)
|
2020-09-25 |
2026-03-17 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
EP4240755A4
(en)
*
|
2020-11-06 |
2024-12-18 |
Board of Regents, The University of Texas System |
Methods and systems for classification and treatment of small cell lung cancer
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
EP4313081A4
(en)
*
|
2021-04-02 |
2025-04-09 |
Nanjing Legend Biotech Co., Ltd. |
MANIPULATED IMMUNE CELLS AND THEIR USES
|
|
WO2023034555A1
(en)
*
|
2021-09-02 |
2023-03-09 |
Memorial Sloan-Kettering Cancer Center |
Antigen recognizing receptors targeting dll3 and uses thereof
|
|
AU2024244733B2
(en)
|
2023-03-31 |
2025-12-11 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
CN117169518B
(zh)
*
|
2023-11-03 |
2024-01-19 |
赛德特(北京)生物工程有限公司 |
T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
|
|
WO2025212519A1
(en)
*
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
WO2026059931A2
(en)
*
|
2024-09-11 |
2026-03-19 |
Telix Targeting Technologies, Inc. |
Dll3 antigen binding constructs
|